NasdaqGS - Nasdaq Real Time Price USD
Arrowhead Pharmaceuticals, Inc. (ARWR)
16.29
+0.55
+(3.49%)
At close: May 20 at 4:00:01 PM EDT
16.25
-0.04
(-0.25%)
Pre-Market: 8:00:01 AM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 12 | 13 |
| Avg. Estimate | -1.1 | -0.5 | -0.18 | -3.45 |
| Low Estimate | -1.29 | -1.48 | -1.27 | -4.72 |
| High Estimate | -0.29 | 1.05 | 1.57 | -1.66 |
| Year Ago EPS | -1.38 | -1.37 | -5 | -0.18 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 15 | 16 |
| Avg. Estimate | 29.01M | 104.6M | 695.31M | 285.94M |
| Low Estimate | -- | -- | 545.2M | 94M |
| High Estimate | 134.7M | 303.3M | 914.5M | 466.95M |
| Year Ago Sales | -- | -- | 3.55M | 695.31M |
| Sales Growth (year/est) | 0.00% | 0.00% | 19,480.80% | -58.88% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -0.59 | -0.92 | -0.72 | -0.46 |
| EPS Actual | -1.38 | -1.37 | -1.39 | 2.75 |
| Difference | -0.79 | -0.45 | -0.67 | 3.21 |
| Surprise % | -134.53% | -48.60% | -92.16% | 695.04% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -1.1 | -0.5 | -0.18 | -3.45 |
| 7 Days Ago | -1.16 | -0.73 | -0.31 | -3.6 |
| 30 Days Ago | -0.94 | -0.56 | -3.32 | -3.83 |
| 60 Days Ago | -1.02 | -0.69 | -3.55 | -3.94 |
| 90 Days Ago | -1.02 | -0.69 | -3.6 | -3.94 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 4 | 6 | 9 | 5 |
| Up Last 30 Days | 4 | 6 | 9 | 5 |
| Down Last 7 Days | 5 | 3 | -- | 4 |
| Down Last 30 Days | 5 | 3 | -- | 4 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| ARWR | 20.19% | 63.53% | 96.43% | -1,830.93% |
| S&P 500 | 13.32% | 2.69% | 7.77% | 13.75% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/20/2025 |
| Maintains | Citigroup: Neutral to Neutral | 5/13/2025 |
| Maintains | Chardan Capital: Buy to Buy | 5/13/2025 |
| Reiterates | B. Riley Securities: Buy to Buy | 2/14/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/12/2025 |
| Reiterates | RBC Capital: Outperform to Outperform | 2/11/2025 |
Related Tickers
ALNY Alnylam Pharmaceuticals, Inc.
291.68
-0.06%
PRQR ProQR Therapeutics N.V.
1.7600
+2.92%
IONS Ionis Pharmaceuticals, Inc.
34.47
+1.29%
SRPT Sarepta Therapeutics, Inc.
39.99
+5.40%
BBIO BridgeBio Pharma, Inc.
33.71
+0.06%
BHVN Biohaven Ltd.
16.25
+3.17%
AXSM Axsome Therapeutics, Inc.
108.35
+0.05%
SGMO Sangamo Therapeutics, Inc.
0.4991
+0.12%
WVE Wave Life Sciences Ltd.
6.54
+1.24%
SLN Silence Therapeutics plc
5.14
+3.63%